Skip to content

Strategies in early arthritis management.

Strategies in early arthritis management.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25364
Enrollment
80
Registered
2005-08-24
Start date
2004-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis, undifferentiated oligo- or polyarthritis

Interventions

Methotrexate, in case of insufficient response followed by adalimumab, and then by a combination of methotrexate, sulfasalazine, hydroxychloroquin and prednisone versus usual care according to prefere

Sponsors

Prof dr BAC Dijkmans VUmc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18+; 2. Symptom duration less than 3 years; 3. Swelling 2-5 joints.

Exclusion criteria

Exclusion criteria: 1. Earlier treatment with disease modifying antirheumatic drugs except hydrxychloroquine; 2. Prednisone use within 3 months; 3. Bacterial arthritis, crystal induced arthritis, reactive arthritis, sarcoidosis, osteoarthritis or systemic autoimmune disease other than RA; 4. Pregnancy; 5. Erosive disease.

Design outcomes

Primary

MeasureTime frame
Progression of radiographic damage score after 2 years.

Secondary

MeasureTime frame
1. Functional capacity; 2. Quality of life; 3. Disease activity.

Contacts

Public ContactD. Schaardenburg, van

Jan van Breemen Institute, Dr. Jan van Breemenstraat 2

d.v.schaardenburg@janvanbreemen.nl+31 (0)20 5896589

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)